Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. AU2002336520 - Method of treating benign prostatic hyperplasia and other beingn porstate conditions

Office
Australie
Numéro de la demande 2002336520
Date de la demande 13.09.2002
Numéro de publication 2002336520
Date de publication 20.02.2003
Type de publication A
CIB
A61K 31/203
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
31Préparations médicinales contenant des ingrédients actifs organiques 
185Acides; Leurs anhydrides, halogénures ou sels, p.ex. acides du soufre, acides imidiques, hydrazoniques ou hydroximiques
19Acides carboxyliques, p.ex. acide valproïque
20ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique
203Acides rétinoïques
CPC
A61K 31/203
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
20having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
203Retinoic acids ; Salts thereof
A61P 13/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
08of the prostate
Déposants PARKS, L., Dean
Inventeurs Parks, L. Dean
Données relatives à la priorité 09953620 17.09.2001 US
Titre
(EN) Method of treating benign prostatic hyperplasia and other beingn porstate conditions
Abrégé
(EN)
Methods of treatment of benign prostatic hyperplasia and reduction of the level of the prostate specific antigen (PSA) of benign prostate conditions are disclosed. The treatment method includes an initial treatment of patients with orally administration of an initial dosage of about 40 mg 13 cis-retinoic acid daily for a period from about ten days to about twenty days, and followed by a sustaining treatment of the patients with orally administration of a sustaining dosage of about 40 mg 13 cis-retinoic acid about every five to seven days in a sustaining period.